Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in C… (NCT07058051) | Clinical Trial Compass
CompletedNot Applicable
Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China
China100 participantsStarted 2025-07-17
Plain-language summary
The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China
This study is a cross-sectional, multicenter, observational study of vitiligo patients in China. The cross-sectional design is sufficient to characterize the overall current burden of NSV.
Who can participate
Age range12 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female patients, age ≥ 12.
* Chinese patients meet the diagnosis of Non-Segmental Vitiligo (NSV) and 5≤ Total Vitiligo Area Scoring Index (T-VASI\<50) with or without facial involvement.
* Medical history available within the last 6 months.
* Ability to understand the questionnaires, with parental support as required for adolescents (between ≥ 12 and \< 18 years of age at inclusion visit).
* Willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable.
Exclusion Criteria:
* Unable or unwilling to comply with study requirements and electronic Patient-Reported Outcome (ePRO) collection.
* Segmental or localized vitiligo.
* Greater than 33% leukotrichia in areas of vitiligo on the face or on the body.
* History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
* Patients who are participating in interventional clinical trial(s) at time of study visit.
* Patients who are currently receiving treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to enrollment.